Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia

Summary Background  Provoked vestibulodynia is difficult to treat. The beneficial effects of botulinum toxin A are being considered because of the muscular anomalies observed in this pathology.

[1]  G. Kirtschig,et al.  Guidelines for the management of vulvodynia , 2010, The British journal of dermatology.

[2]  L. Lundvall,et al.  Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. , 2009, The journal of sexual medicine.

[3]  D. Rapp,et al.  Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation , 2008, BJU international.

[4]  S. Bergeron,et al.  The Treatment of Provoked Vestibulodynia: A Critical Review , 2008, The Clinical journal of pain.

[5]  M. Jantos.  Vulvodynia: A Psychophysiological Profile Based on Electromyographic Assessment , 2008, Applied psychophysiology and biofeedback.

[6]  V. Tugnoli,et al.  Botulinum Toxin for Pain , 2008, Drugs in R&D.

[7]  A. Bulbena,et al.  Clinical Characteristics and Psychopathological Profile of Patients with Vulvodynia: An Observational and Descriptive Study , 2007, Dermatology.

[8]  J. Dolly,et al.  Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential , 2007, Journal of Cell Science.

[9]  B. Fenton.  Limbic associated pelvic pain: a hypothesis to explain the diagnostic relationships and features of patients with chronic pelvic pain. , 2007, Medical hypotheses.

[10]  B. Shim,et al.  Botulinum toxin A for the management of vulvodynia , 2007, International Journal of Impotence Research.

[11]  P. Humbert,et al.  Vestibulite vulvaire : traitement par la toxine botulinique , 2006 .

[12]  Candace S. Brown,et al.  Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. , 2006, The Journal of reproductive medicine.

[13]  D. Dykstra,et al.  Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study. , 2006, The Journal of reproductive medicine.

[14]  V. Pinn,et al.  Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. , 2006, The Journal of reproductive medicine.

[15]  Y. Binik,et al.  Pelvic floor muscle functioning in women with vulvar vestibulitis syndrome , 2005, Journal of psychosomatic obstetrics and gynaecology.

[16]  M. Moyal-Barracco,et al.  The Vulvodynia Guideline , 2005, Journal of lower genital tract disease.

[17]  R. Rosen,et al.  The Female Sexual Function Index (FSFI): Cross-Validation and Development of Clinical Cutoff Scores , 2005, Journal of sex & marital therapy.

[18]  L. Bertolasi,et al.  Botulinum Toxin for the Treatment of Genital Pain Syndromes , 2004, Gynecologic and Obstetric Investigation.

[19]  M. Moyal-Barracco,et al.  2003 ISSVD terminology and classification of vulvodynia: a historical perspective. , 2004, The Journal of reproductive medicine.

[20]  O. Tawfik,et al.  Botulinum toxin a for vulvodynia: a case report. , 2004, The journal of pain : official journal of the American Pain Society.

[21]  P. Anand,et al.  Increased vanilloid receptor VR1 innervation in vulvodynia , 2004, European journal of pain.

[22]  J. Abbott,et al.  Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles , 2004, The Australian & New Zealand journal of obstetrics & gynaecology.

[23]  K. Aoki.  Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management , 2003, Headache.

[24]  G. Terenghi,et al.  Increased innervation of the vulval vestibule in patients with vulvodynia , 2003, The British journal of dermatology.

[25]  B. Harlow,et al.  A population-based assessment of chronic unexplained vulvar pain: have we underestimated the prevalence of vulvodynia? , 2003, Journal of the American Medical Women's Association.

[26]  E. Torebjörk,et al.  Psychophysical evidence of nociceptor sensitization in vulvar vestibulitis syndrome , 2001, Pain.

[27]  R. Galask,et al.  Psychosexual aspects of vulvar vestibulitis. , 2001, The Journal of reproductive medicine.

[28]  Candace S. Brown,et al.  The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. , 2000, Journal of sex & marital therapy.

[29]  M. Hilliges,et al.  Neurochemical Characterization of the Vestibular Nerves in Women with Vulvar Vestibulitis Syndrome , 1999, Gynecologic and Obstetric Investigation.

[30]  P. Weijenborg,et al.  Difficulties in the differential diagnosis of vaginismus, dyspareunia and mixed sexual pain disorder. , 1995, Journal of psychosomatic obstetrics and gynaecology.

[31]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[32]  L. Fertitta,et al.  Vulvar vestibulitis syndrome. , 1992, Nurse practitioner forum.

[33]  A. Carlsson.  Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale , 1983, Pain.